Wave Life Sciences Ltd. (WVE) stock news
The latest Wave Life Sciences Ltd. news and press releases. 0 news stories in the last 24 hours. WVE stock report · Market news
Latest news
- Wave Life Sciences: Reversing Stock Losses Tricky Despite Near-Term AATD Readout Seeking Alpha, Nov 10, 6:55 PM UTC
Wave Life Sciences, Inc. remains a 'Hold,' as I see limited near-term upside amid competitive obesity and AATD markets. WVE-007's modest ~1% weight loss at six months lags GLP-1 peers, though muscle preservation and d... - Wave: 3 Key Takeaways for Long-Term Investors The Motley Fool, Nov 8, 11:00 PM UTC
Wave aligned with the FDA on a single trial for WVE-006. Cash and marketable securities reached $431 million to fund operations into 2028. - Wave Life Sciences, Inc. (WVE) Research Day: RNA Medicines Platform and Pipeline Innovation Transcript Seeking Alpha, Nov 4, 11:24 PM UTC
Wave Life Sciences, Inc. (WVE) Research Day: RNA Medicines Platform and Pipeline Innovation Transcript - WAVE Life Sciences Targets Genetic Liver Disease With WVE-008 RNA Editing Program MarketBeat, Nov 4, 7:15 PM UTC
WAVE Life Sciences NASDAQ: WVE used its 2026 Research Day to outline plans for WVE-008, an RNA-editing candidate being developed for liver disease associated with the PNPLA3 I148M genetic variant, while also providing... - Wave Life Sciences, Inc. (WVE) Q3 2026 Earnings Call Transcript Seeking Alpha, Oct 27, 6:40 PM UTC
Wave Life Sciences, Inc. (WVE) Q3 2026 Earnings Call Transcript - WAVE Life Sciences Q3 Earnings Call Highlights MarketBeat, Oct 27, 5:07 PM UTC
WAVE Life Sciences NASDAQ: WVE reported higher third-quarter revenue and a wider net loss as it increased investment in clinical programs spanning obesity, alpha-1 antitrypsin deficiency and liver disease. - Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue Estimates Zacks Investment Research, Oct 27, 1:41 PM UTC
Wave Life Sciences (WVE) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.32 per share a year ago. - WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path MarketBeat, Oct 22, 3:03 AM UTC
WAVE Life Sciences NASDAQ: WVE outlined progress across its obesity-focused siRNA program and RNA editing pipeline during a Chardan discussion, with President and CEO Paul Bolno emphasizing the company's chemistry pla... - WAVE Life Sciences (NASDAQ:WVE) Sets New 1-Year Low – Here’s Why Defense World, Oct 12, 4:34 PM UTC
WAVE Life Sciences Ltd. (NASDAQ: WVE - Get Free Report)'s share price reached a new 52-week low during trading on Monday. The company traded as low as $3.37 and last traded at $3.3850, with a volume of 317,423 shares ... - Analyzing Tonix Pharmaceuticals (NASDAQ:TNXP) and WAVE Life Sciences (NASDAQ:WVE) Defense World, Oct 5, 7:00 AM UTC
WAVE Life Sciences (NASDAQ: WVE - Get Free Report) and Tonix Pharmaceuticals (NASDAQ: TNXP - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies... - WAVE Life Sciences (NASDAQ:WVE) Shares Climb 9.3% – Here’s What Happened Defense World, Oct 3, 9:01 AM UTC
Shares of WAVE Life Sciences Ltd. (NASDAQ: WVE - Get Free Report) rose 9.3% on Thursday. The company traded as high as $4.02 and last traded at $4.0440. 544,448 shares were traded during mid-day trading, a decline of ... - WAVE Life Sciences (NASDAQ:WVE) Shares Gap Up – Time to Buy? Defense World, Oct 2, 9:41 AM UTC
Shares of WAVE Life Sciences Ltd. (NASDAQ: WVE - Get Free Report) gapped up before the market opened on Wednesday. The stock had previously closed at $3.64, but opened at $3.79. WAVE Life Sciences shares last traded a... - 4 RNA Therapeutics Stocks Leading the Next Wave of Innovation Zacks Investment Research, Sep 28, 4:01 PM UTC
RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases. - Comparing WAVE Life Sciences (NASDAQ:WVE) and Septerna (NASDAQ:SEPN) Defense World, Sep 22, 10:15 AM UTC
Septerna (NASDAQ: SEPN - Get Free Report) and WAVE Life Sciences (NASDAQ: WVE - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based... - These beaten-down stocks could bounce back in January, if history is any guide Market Watch, Sep 21, 9:06 PM UTC
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
Press releases
- Wave Life Sciences Highlights WVE-007 (INHBE siRNA) Progress at ObesityWeek® 2026 GlobeNewsWire, Nov 13, 1:30 PM UTC
INLIGHT Phase 1 data continue to support WVE-007's novel mechanism of action to improve body composition by inducing fat loss without muscle loss, and support a once- or twice-yearly dosing regimen - Wave Life Sciences to Present at Jefferies Global Healthcare Conference in London GlobeNewsWire, Nov 11, 1:30 PM UTC
CAMBRIDGE, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, t... - Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update GlobeNewsWire, Oct 27, 11:30 AM UTC
Planning underway for registrational trial of WVE-006 (RNA editing) in AATD, with an interim analysis for potential accelerated approval based on AATD biomarkers - Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026 GlobeNewsWire, Oct 20, 12:30 PM UTC
CAMBRIDGE, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, w... - Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026 GlobeNewsWire, Oct 19, 12:30 PM UTC
CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, a... - Wave Life Sciences to Present at Chardan's 10th Annual Healthcare Conference GlobeNewsWire, Oct 13, 12:30 PM UTC
CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, t... - Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD GlobeNewsWire, Oct 1, 11:30 AM UTC
Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers - Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development GlobeNewsWire, Sep 30, 11:30 AM UTC
Candidate selected by GSK utilizes Wave's best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing - Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity GlobeNewsWire, Sep 23, 11:30 AM UTC
WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave's INHBE GalNAc-siRNA in combination with GLP-1 doubled weight loss compared with GLP-... - Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer GlobeNewsWire, Sep 22, 11:30 AM UTC
Dr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Blackstone, and Pfizer CAMBRIDGE, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. - Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference GlobeNewsWire, Sep 3, 8:05 PM UTC
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
Headlines link to their publishers. Research data, not investment advice.